BioCryst Pharmaceuticals (BCRX) Projected to Post Quarterly Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 5th. Analysts expect BioCryst Pharmaceuticals to post earnings of ($0.07) per share and revenue of $126.83 million for the quarter.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analysts' expectations of $126.64 million. The business's quarterly revenue was up 40.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.28 earnings per share. On average, analysts expect BioCryst Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioCryst Pharmaceuticals Stock Performance

BCRX traded down $0.14 on Thursday, reaching $8.71. 3,829,246 shares of the company's stock were exchanged, compared to its average volume of 2,829,752. The company's 50 day moving average is $7.67 and its 200-day moving average is $7.78. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -14.28 and a beta of 1.75. BioCryst Pharmaceuticals has a twelve month low of $4.15 and a twelve month high of $9.50.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. JMP Securities reissued a "market outperform" rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Needham & Company LLC reissued a "buy" rating and set a $15.00 target price on shares of BioCryst Pharmaceuticals in a research report on Thursday, April 10th. Wedbush started coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price target for the company. Royal Bank of Canada restated an "outperform" rating and issued a $11.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, April 11th. Finally, HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.13.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.